Immunovant Inc. (IMVT)
NASDAQ: IMVT
· Real-Time Price · USD
15.96
-0.19 (-1.18%)
At close: May 01, 2025, 3:59 PM
16.39
2.66%
Pre-market: May 02, 2025, 07:19 AM EDT
Company Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia.
The company was incorporated in 2018 is headquartered in New York, New York.
Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant Inc.
| Country | United States |
| IPO Date | Jun 21, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 207 |
| CEO | Dr. Eric Venker M.D., Pharm.D. |
Contact Details
Address: 320 West 37th Street New York, New York United States | |
| Website | https://immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric Venker M.D., Pharm.D. | Chief Executive Officer & Director |
| Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Dr. Jay S. Stout Ph.D. | Chief Technology Officer |
| Melanie Gloria B.S.N. | Chief Operating Officer |
| Andy Deig | Senior Vice President of Strategic Finance |
| Christine Blodgett | Senior Vice President of Human Resources |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Dr. Michael Geffner M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Julie Kirschling | Senior Vice President of Program & Alliance Management |
| Lauren Schrier M.B.A. | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | S-8 | Filing |
| Apr 28, 2025 | 3 | Filing |
| Apr 28, 2025 | 3 | Filing |
| Apr 28, 2025 | 3 | Filing |
| Apr 25, 2025 | 4 | Filing |
| Apr 25, 2025 | 4 | Filing |
| Apr 21, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Apr 21, 2025 | 8-K | Current Report |
| Apr 17, 2025 | 4 | Filing |
| Apr 17, 2025 | 4 | Filing |